Edgewise Therapeutics, Inc. (EWTX) Price Target Analysis
Updated Jul 2, 2026
Analyst Rating: Buy
Based on 10 analysts10.3% Below Target
EWTX trades 10.3% below Wall Street's consensus target of $47.56.
Current Price$43.13
Average Target$47.56
Target
Current
Low$25.00
Median$52.00
High$66.00
Analyst Target Range
Forward P/E—
PEG Ratio—
Implied Growth-19.3%
(Declining)
Analyst Spread86.2%
(Wide Disagreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes EWTX achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 10 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
EWTX Price Target Analysis
Updated July 8, 2026As of July 8, 2026, Edgewise Therapeutics, Inc. (EWTX) has a Wall Street consensus price target of $47.56, based on estimates from 10 covering analysts. With the stock currently trading at $43.13, this represents a potential upside of +10.3%. The company has a market capitalization of $4.64B.
Analyst price targets range from a low of $25.00 to a high of $66.00, representing a 86% spread in expectations. The median target of $52.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, EWTX trades at a trailing P/E of -26.5x. Analysts expect EPS to grow -19.3% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+37.0%
Industry Consensus
Avg Forward P/E
81.1x
(High Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ACADACADIA Pharmaceuticals Inc. | $4.5B | $26.20 | $34.38 | +31.2% | Buy | 68.9x | 37 |
 KYMRKymera Therapeutics, Inc. | $9.7B | $119.24 | $125.29 | +5.1% | Buy | — | 27 |
 CMPSCOMPASS Pathways plc | $1.2B | $12.99 | $18.57 | +43.0% | Buy | — | 13 |
 IMVTImmunovant, Inc. | $8.2B | $40.09 | $45.00 | +12.2% | Buy | — | 23 |
 ARQTArcutis Biotherapeutics, Inc. | $3.5B | $27.67 | $34.00 | +22.9% | Buy | 138.6x | 12 |
 PRAXPraxis Precision Medicines, Inc. | $9.4B | $323.95 | $589.00 | +81.8% | Buy | — | 16 |
 MGTXMeiraGTx Holdings plc | $1.4B | $14.66 | $25.00 | +70.5% | Buy | — | 6 |
 MDGLMadrigal Pharmaceuticals, Inc. | $12.6B | $545.36 | $656.00 | +20.3% | Buy | — | 23 |
 URGNUroGen Pharma Ltd. | $1.8B | $37.75 | $42.50 | +12.6% | Buy | — | 15 |
 TMDXTransMedics Group, Inc. | $2.5B | $71.11 | $121.20 | +70.4% | Buy | 36.0x | 12 |
EWTX — Frequently Asked Questions
Quick answers to the most common questions about buying EWTX stock.
What is the EWTX stock price target for 2026?
Edgewise Therapeutics, Inc. (EWTX) has a consensus 12-month price target of $47.56, implying 10.3% upside from $43.13. The 10 analysts covering EWTX see moderate appreciation potential.
Is EWTX a buy, sell, or hold?
EWTX has a consensus rating of "Buy" based on 10 Wall Street analysts. The rating breakdown is predominantly bullish, with 8 Buy/Strong Buy ratings. The consensus 12-month price target of $47.56 implies 10.3% upside from current levels.
Is EWTX stock overvalued or undervalued?
EWTX's current price is $43.13 with a consensus target of $47.56 (10.3% implied move). Analyst estimates suggest the stock is undervalued at current levels.
How high can EWTX stock go?
The most bullish Wall Street analyst has a price target of $66 for EWTX, while the most conservative target is $25. The consensus of $47.56 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover EWTX stock?
EWTX is moderately covered, with 10 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the EWTX stock forecast?
The 12-month EWTX stock forecast based on 10 Wall Street analysts shows a consensus price target of $47.56, with estimates ranging from $25 (bear case) to $66 (bull case). The median consensus rating is "Buy".
Should I buy EWTX stock?
Wall Street analysts are optimistic on EWTX, with a "Buy" consensus rating and $47.56 price target (10.3% upside). 8 of 10 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do EWTX price targets vary so much?
EWTX analyst price targets range from $25 to $66, a 86% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $47.56 consensus represents the middle ground.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare